Exabis Library
Welcome to the e-CCO Library!
OP01: Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP02 Impact of therapeutic strategies on intestinal resection rate in paediatric inflammatory bowel diseases: A population-based cohort study over a 24-year period (1988–2011)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP020: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: interim analysis from the Phase 2 FITZROY study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP020: The clinical determinants affect gut microbial profile of inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP021: Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP021: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP022: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP023: Comparison between newly developed narrow band imaging and panchromoendoscopy for surveillance colonoscopy in patients with ulcerative colitis: a prospective multicentre randomised controlled trial, navigator study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP023: Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP024: Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP024: Mucosal healing and dysplasia surveillance in a large referral Centre cohort of patients with Crohn’s disease and ulcerative colitis treated with vedolizumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP025: Escalation of medical therapy decreases need for repeat dilatation in Crohn’s anastomatic strictures
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM